Go to Content Go to Navigation Go to Navigation Go to Site Search Homepage

Statement from Dr. Vanessa Cullins, Planned Parenthood Vice President of External Medical Affairs, on the Food and Drug Administration’s Label Change for Drospirenone-Containing Birth Control Pills

Source

Planned Parenthood Federation of America

Published

April 11, 2012

As the nation’s leading and most trusted provider of reproductive health care, Planned Parenthood understands the importance of patients having the information they need to make informed health care decisions.

“The Food and Drug Administration’s decision to keep drospirenone-containing birth control pills on the market without additional restrictions, but to include more information about their risks and benefits on packaging will help women and their providers make more informed decisions when selecting birth control methods,” said Dr. Vanessa Cullins. 

“Hormonal contraceptives are among the most effective methods of pregnancy prevention.  And though some studies have shown that women are at a slightly higher risk for blood clots when using drospirenone-containing formulations, the occurrence of blood clots while using these methods is still extremely rare, and the risk is significantly less than what women experience during pregnancy and postpartum.  Moreover the increase in risk seen with drospirenone-containing birth control pills is similar to that found with other accepted and commonly used birth control pills.  The important take-home here is that while women and their providers should be aware of these risks when making decisions about birth control, they should not be overly concerned by this new information.”

 

Source

Planned Parenthood Federation of America

Contact

Shawn Rhea (212) 273-6740 / [email protected]

Published

April 11, 2012

We and our third partners use cookies and other tools to collect, store, monitor, and analyze information about your interaction with our site to improve performance, analyze your use of our sites and assist in our marketing efforts. You may opt out of the use of these cookies and other tools at any time by visiting Cookie Settings. By clicking “Allow All Cookies” you consent to our collection and use of such data, and our Terms of Use. For more information, see our Privacy Notice.

Cookie Settings

We, and our third-party partners, use cookies, pixels, and other tracking technologies to collect, store, monitor, and process certain information about you when you access and use our services, read our emails, or otherwise engage with us. The information collected might relate to you, your preferences, or your device. We use that information to make the site work, analyze performance and traffic on our website, to provide a more personalized web experience, and assist in our marketing efforts. We also share information with our social media, advertising, and analytics partners. You can change your default settings according to your preference. You cannot opt-out of required cookies when utilizing our site; this includes necessary cookies that help our site to function (such as remembering your cookie preference settings). For more information, please see our Privacy Notice.

Marketing

On

We use online advertising to promote our mission and help constituents find our services. Marketing pixels help us measure the success of our campaigns.

User Feedback and Session Replay

On

We use qualitative data from LogRocket, UserZoom, Hotjar and AB Tasty to learn about your user experience and improve our products and services. LogRocket allows us to view session replays.